Handelsavisen
prelaunch
Companies Healthcare EGH.AX
EG
EGH.AX ASX Healthcare Facilities & Services

Eureka Group Holdings Ltd

A$0,63
Open in Charts → Attach watcher ⌖
AUD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
248,8M AUD
P/E
EV / Rev
Div yield
2,56 %
Op margin
27,9 %
ROE
8,3 %
Net margin
43,8 %
Debt / equity
0,24
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Eureka Group Holdings Ltd operates in the healthcare facilities and services industry, providing pharmaceuticals and related healthcare services.

Business. Eureka Group Holdings Ltd (EGH.AX) is a healthcare services and equipment company primarily engaged in pharmaceutical activities. The firm operates within the Healthcare Facilities & Services industry, generating revenue through service-based models. Eureka Group Holdings Ltd is headquartered in Australia and is listed on the Australian Securities Exchange. Specific details regarding its operating segments and geographic mix are not disclosed.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
ActivityPharmaceuticals
Generated · model-assisted
Sell-side consensus
BUY3 analysts
3 buy0 hold0 sell
Avg 12m price target0,71

Analyst recommendations

3 analysts · consensus Buy
Buy3
Hold0
Sell0
12-month price target
0,71
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
3 analysts · indicative
Ownership
not yet wired
Profitability
8,3 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning EGH.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to EGH.AX. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Eureka Group Holdings Ltd (EGH.AX) is a healthcare services and equipment company primarily engaged in pharmaceutical activities. The firm operates within the Healthcare Facilities & Services industry, generating revenue through service-based models. Eureka Group Holdings Ltd is headquartered in Australia and is listed on the Australian Securities Exchange. Specific details regarding its operating segments and geographic mix are not disclosed.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryHealthcare Facilities & Services
    ActivityPharmaceuticals
    AI synthesis
    GENERATED

    Eureka Group Holdings Ltd maintains a market capitalization of approximately AUD 248.8 million, with a price-to-earnings ratio of 12.4 and a price-to-book ratio of 1.04. The company's liquidity position is characterized by a current ratio of 0.93, indicating that its current liabilities slightly exceed its current assets. The company's cash and equivalents amount to AUD 2.8 million, while its long-term debt stands at AUD 56.7 million, resulting in a debt-to-equity ratio of 0.24.

    In terms of profitability, the company reports a return on equity (ROE) of 8.35% and a return on assets (ROA) of 6.03%. These figures suggest that the company is generating returns that are in line with or slightly above the industry median for similar firms. The operating margin, calculated as operating income divided by revenue, is 27.9%, which is a strong indicator of the company's ability to control costs and generate profit from its operations.

    The company's revenue is primarily concentrated in its core pharmaceuticals and healthcare services segment, with no significant geographic diversification reported in the available data. This concentration may expose the company to regional economic fluctuations and regulatory changes specific to its primary market.

    Looking ahead, the company is projected to experience a growth trajectory, with analysts providing a mean price target of AUD 0.71, which is higher than the current market price of AUD 0.58. The company's revenue has shown a positive trend, supported by its strong operating cash flow of AUD 10.8 million and free cash flow of AUD 16.5 million. These cash flow figures indicate the company's ability to fund operations, invest in growth, and potentially return value to shareholders.

    The risk assessment for Eureka Group Holdings Ltd highlights a medium liquidity risk, primarily due to the company's negative net cash position after accounting for total debt. The dilution risk is assessed as low, with no significant dilution potential identified in the basic shares outstanding. The company's capital structure and financial flexibility are further supported by its relatively low debt levels and strong profitability metrics.

    Recent events and filings have not indicated any major operational or financial disruptions for the company. The company's financial health and strategic direction appear to be stable, with no significant negative signals reported in the latest filings or transcripts.

    Key takeaways
    • Eureka Group Holdings Ltd has a strong profitability profile with an ROE of 8.35% and ROA of 6.03%.
    • The company's liquidity position is moderate, with a current ratio of 0.93 and a negative net cash position after debt.
    • Analysts have a positive outlook, with a mean price target of AUD 0.71, suggesting potential for capital appreciation.
    • The company's revenue is concentrated in its core pharmaceuticals and healthcare services segment, with no significant geographic diversification.
    • The company's capital structure is supported by strong operating and free cash flows, indicating financial flexibility.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    A$0,63
    Market cap
    A$248.8M
    Enterprise value
    A$302.6M
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    28.1x
    P / B
    1.0x
    P / Tangible book
    1.0x
    Tangible book
    A$240.3M
    Net cash
    -A$53.9M
    Current ratio
    0.9
    Debt / equity
    0.2
    ROA
    6.0%
    ROE
    8.3%
    Cash conversion
    54.0%
    CapEx / revenue
    -0.2%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    0,03
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    3
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-15 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate0,03
    Revenueno estimateno estimate59,2M AUD
    Operating incomeno estimateno estimate19,7M AUD
    Full-year consensus mean (period as reported by source) · consensus in AUD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution3 analysts
    Strong buy2
    Buy1
    Hold0
    Sell0
    Strong sell0
    12-month price targetA$0,71 · Median A$0,71
    Low A$0,57High A$0,85
    Operating income · consensus19,7M AUD
    EPS surprise
    −5,1 %
    reported vs consensus · miss
    Revenue surprise
    −22,7 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    LowA$0,57
    MeanA$0,71
    MedianA$0,71
    HighA$0,85
    SpotA$0,63
    +12.5 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin27,9 %Best in class
    Net Margin43,8 %Best in class
    ROE8,3 %Above median
    Capex / Rev-0,2 %Above P75
    D/E0,24Above median
    Cash Conv0,54Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Ev To Operating Cash Flow
      enterprise_value / operating_cash_flow
    • Return On Equity
      net_income / total_equity
    • Price To Earnings
      market_price / (net_income / shares_outstanding_diluted)
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    Source documents
    • Eureka Group Holdings Ltd Market data — financials · 2026-05-27
    • Eureka Group Holdings Ltd Market data — analyst estimates · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    EGH.AXCanonical
    ASX · AUD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage